Germany Daily Briefing

Morgan Stanley revamped its Oracle price target following the one-two punch of Ellison's share-sale filing and subsequent cancellation. The revision reflects updated modeling of Oracle's AI data centre revenue trajectory versus capital expenditure commitments. For German investors with US tech exposure, the Oracle saga is a proxy debate for the broader hyperscaler capex cycle — whether AI infrastructure spending is compounding or plateauing is the single most important variable for European tech valuations given cross-listing and derivative exposure.

BioNTech co-investor Thomas Strüngmann told FAZ Finanzen that the appetite-suppressant drug market — dominated by Novo Nordisk and Eli Lilly — will become far larger than current forecasts, calling the weight-loss injection segment a structural rather than cyclical winner. For Germany's pharma and biotech sector, Strüngmann's credibility — built through early BioNTech investment — adds weight to the GLP-1 drug thesis. German biopharma names partnering in the obesity space stand to benefit if his prediction materializes into expanded licensing or clinical partnership deals.

Bernard Arnault's fortune fell $65 billion in 2026 to $143 billion, ejecting him from the top-10 richest for the first time since 2017. As Economic Times reported, US technology billionaires now dominate the rankings as LVMH's stock suffers from synchronized luxury demand softness in China, the US, and Europe. For DAX investors, the Arnault story has indirect but meaningful transmission: Germany's HUGO BOSS and luxury-adjacent auto brands (Porsche, Mercedes) face the same China-demand headwind that has eroded LVMH's multiple — watch Q3 earnings for any signs of divergence from the peer luxury selloff.